Immunogenicity of therapeutic monoclonal antibodies

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 2, 2003, Pages 172-179

  Pendley, Charles ^a   Schantz, Allen ^a   Wagner, Carrie ^a  

^a CENTOCOR INC   (United States)

Author keywords

Efficacy; Immune response; Immunogenicity; Monoclonal antibody; Therapeutics

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; CD20 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD52 ANTIGEN; DACLIZUMAB; ETANERCEPT; FIBRINOGEN RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; OKT 3; ONCOPROTEIN; PALIVIZUMAB; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANALYTIC METHOD; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B CELL LYMPHOMA; BIOASSAY; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; GOAT; GRAFT REJECTION; HEADACHE; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG DISEASE; MONKEY; MOUSE; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PREDICTION; PSORIATIC ARTHRITIS; RADIOIMMUNOASSAY; RADIOIMMUNOPRECIPITATION; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SURFACE PLASMON RESONANCE; UNITED STATES; UNSTABLE ANGINA PECTORIS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY; RADIOIMMUNOASSAY; SURFACE PLASMON RESONANCE;

CAPRA HIRCUS; PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS;

EID: 0038476357     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Orthoclone OKT-3: Ortho Biotech Products Package Insert (2001).
2. Gura T: Therapeutic antibodies: Magic bullets hit the target. Nature (2002) 417(6889):584-586.
3. Schellekens H: Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther (2002) 24(11):1720-1740.
4. Fineberg SE, Galloway JA, Fineberg NS, Rathbun W, Hufferd S: Immunogenicity of recombinant DNA human insulin. Diabetologia (1983) 25(6):465-469.
5. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibell E, White G 3rd, Lee M: A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood (1994) 83(9):2428-2435.
6. Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF: Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst (1988) 80(12):937-942.
7. Knight DM, Wagner C, Jordan R, McAleer MF, Derita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J: The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol (1995) 32(16):1271-1281.
8. Avrameas S: Natural autoantibodies: Self-recognition and physiological autoimmunity. In: Natural Autoantibodies, their Physiological Role and Regulatory Significance. Shoenfeld Y, Isenberg DA (Eds), CRC Press, London, UK (1993):1-14.
9. Persselin JE, Stevens RH: Anti-Fab antibodies in humans: Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest (1985) 76(2):723-730.
10. Taylor R, Sutherland WM, Martin EN, Ferguson PJ, Reinagel ML, Gilbert E, Lopez K, Incardona NL, Ochs HD: Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J Immunol (1997) 158(2):842-850.
11. Jefferis R, Lund J: Interaction sites on human IgG-Fc for FcγR: Current models. Immunol Lett (2002) 82(1-2):57-65.
12. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB: Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med (1995) 1(3):237-243.
13. Foerder CA. Rogge MC: Immunogenicity of Enbrel® (Etanercept): Clinical trial observations. Ann Rheum Dis (2002) 61 (Suppl 1):72.
14. Abrantes M, Magone MT, Boyd LF, Schuck P: Adaptation of a surface plasmon resonance biosensor with microfluidics for use with small sample volumes and long contact times. Anal Chem (2001) 73(13):2828-2835.
15. Sandhu J, Shpitz B, Gallinger S, Hozumi N: Human primary Immune response in SCID mice engrafted with human peripheral blood lymphocytes. J Immunol (1994) 152(8):3806-3813.
16. Boynton E, Aubin J, Gross A, Hozumi N, Sandhu J: Human osteoblasts survive and deposit new bone when human bone is implanted In SCID mouse. Bone (1996) 18(4):321-326.
17. Carballido JM, Namikawa R, Carballido-Perrig N, Antonenko S, Roncarolo MG, de Vries J: Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice. Nat Med (2000) 6(1):103-106.
18. Brams P, Nguyen ML, Chamat S, Royston I, Morrow PR: Antigen-specific IgG responses from naive human splenocytes: In vitro priming followed by antigen boost in the SCID mouse. J Immunol (1998) 160(5):2051-2058.
19. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ: Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor γ chain. Br J Haematol (1998) 103(2):335-342.
20. Podesta M, Pitto A, Figari O, Bacigalupo A, Bruzzone S, Guida L, Franco L, De Flora A, Zocchi E: Cyclic ADP-ribose generation by CD38 improves human hemopoietic stem cell engraftment into NOD/SCID mice. FASEB J (2003) 17(2):310-312.
21. Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R, Laraya P, Minden M, Keating A, Eaves AC et al: High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoetic cells from patients with chronic myeloid leukemia in chronic phase. Blood (1998) 91(7):2406-2414.
22. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, Bodmer M: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology (1995) 85(4):668-674.
23. Stickler M, Mucha J, Estell D, Power S, Harding F: A human dendritic cell-based method to identify CD4+ T-cell epitopes in potential protein allergens. Environ Health Perspect (2003) 111(2):251-254.
24. Warmerdam PA, Plaisance S, Vanderlick K, Vandervoort P, Brepoels K, Collen D, De Maeyer M: Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemost (2002) 87(4):666-673.
25. MHCPEP: A database of MHC binding peptides: The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia (1998). http://wehih.wehi.edu.au/mhcpep/
26. SYFPEITHI: A database of MHC ligands and peptide motifs: Institute for Cell Biology, Department of Immunology, Heidelberg, Germany (2003). http://syfpeithi.bmi-heidelberg.com/scripts/mhcserver.dll/home.htm.
27. HLA peptide binding predictions: Bioinformatics and Molecular Analysis Section, MD, USA (2003). http://bimas.dcrt.nih.gov/molbio/hla_bind
28. ProPred MHC class-II binding peptide prediction server: Institute of Microbial Technology, Chandigarh, India (2003). http://www.imtech.res.in/raghava/propred
29. TEPITOPE-2000: Vaccinome, Milan, Italy (2003). http://www.vaccinome.com
30. EpiMatrix: Epivax Inc, Providence, RI, USA (2003). http://www.epivax.com/epimatrix.html
31. Wagner C: Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade®. In: Immunogenicity of Therapeutic Biological Products. Brown F, Mire-Slluis AR (Eds), Karger AG, Basel, Switzerland (2003)112:37-53.
32. Wagner C, Olson A, Ford J, Bao W, Patel K, Hanauer S: Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohn's disease. Gastroenterology (2002) 122:Poster W1345.
33. Synagis®: MedImmune Inc Package Insert (2002).
34. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 348(7):601-608.
35. Humira®: Abbott Laboratories Package Insert (2003).
36. Herceptin®: Genentech Inc Package Insert (2002).
37. Rituxan®: Genentech Inc/IDEC Pharmaceuticals Corp Package Insert (2002).
38. Campath®: Millenium and ILEX Partners Package Insert (2001).
39. Simulect®: Novartis Pharmaceuticals Corp Package Insert (2003).
40. Enbrel™: Immunex Corp Package Insert (2002).
41. Remicade®: Centocor Inc Package Insert (2003).
42. Wagner CL, St Clair EW, Han C, Ford J, Schantz A, Maini R, Lipsky P: Effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT study. Arthritis Rheum (2002) 46:3132.
43. Zenapax®: Roche Pharmaceutical Package Insert (1999).
44. ReoPro®: Centocor Inc Package Insert (2003).